focus -WSS

focus

author：fashion 2025-09-27 16:48:34 - browse：8

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Ukraine seeks to reclaim its role as a hub for clinical trials

knowledge

focus

WSS

New Covid vaccine is recommended for everyone 6 months or older

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

White House touts steps to stem shortages of cancer treatments

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

FDA approves updated Covid vaccines

Congress may force more Covid

explore

focus

Wikipedia

New air purifier tech could be key to improving indoor air quality

Food makers tried to stack nutrition panel with preferred experts

As demand for Covid shots wanes, Moderna seeks its next success

White House touts steps to stem shortages of cancer treatments

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

As demand for Covid shots wanes, Moderna seeks its next success

New CMS data security rules will hurt Medicare, Medicaid research

Medicare details structure of new drug price negotiation program

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

entertainment

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Weight loss drugs aren’t covered by Obamacare. That may change

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Food makers to regulators: Ultra

White House touts steps to stem shortages of cancer treatments

White House touts steps to stem shortages of cancer treatments

leisure time

knowledge

focus

knowledge